POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
Potassium chloride replaces potassium ions, essential for maintaining cellular membrane potential, nerve impulse conduction, and muscle contraction. Dextrose 5% provides 5% glucose as a caloric source. Lactated Ringer's solution contains electrolytes (sodium, potassium, calcium, chloride) and lactate (bicarbonate precursor) to restore fluid and electrolyte balance.
| Metabolism | Potassium is primarily absorbed and eliminated by the kidneys; not metabolized. Dextrose is metabolized via glycolysis and the Krebs cycle. Lactate is converted to bicarbonate in the liver. |
| Excretion | Primarily renal (>90%) via glomerular filtration and distal tubular secretion; minimal fecal loss (<10%). |
| Half-life | Not applicable; potassium is an electrolyte with no true elimination half-life. In overdose, redistribution from extracellular to intracellular compartments occurs with a half-life of approximately 2-3 hours. |
| Protein binding | Not significantly protein-bound (<5%). |
| Volume of Distribution | 0.3-0.4 L/kg (total body water distribution; potassium is primarily intracellular). |
| Bioavailability | Oral: 90-100% (well-absorbed). Intravenous: 100%. |
| Onset of Action | Intravenous infusion: Immediate upon administration (1-2 minutes). |
| Duration of Action | As long as infusion continues; after cessation, effects last minutes to hours depending on total body potassium balance. |
IV infusion of 10 mEq/hour, not to exceed 20 mEq/hour; maximum 40 mEq per dose, typically administered in 100-1000 mL solution over 2-4 hours.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25-50%; GFR 10-29 mL/min: reduce dose by 50-75%; GFR <10 mL/min: avoid use unless plasma potassium is severely depleted and ECG monitoring is available. |
| Liver impairment | No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh class C) due to increased risk of hyperkalemia from reduced hepatic clearance. |
| Pediatric use | IV infusion of 0.5-1 mEq/kg per dose, not to exceed 40 mEq/day; administer at a rate of 0.3-0.5 mEq/kg/hour with continuous ECG monitoring. |
| Geriatric use | Initiate at low end of dosing range (0.5 mEq/kg/h); monitor renal function and serum potassium closely due to age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
| Breastfeeding | Potassium is a normal component of breast milk. Maternal administration of potassium chloride at recommended doses does not pose a risk to the nursing infant. The milk-to-plasma ratio is approximately 0.1-0.3 for potassium, but specific M/P ratio for this preparation is not established. Use is considered compatible with breastfeeding. |
| Teratogenic Risk | Potassium chloride is a normal constituent of body fluids and is not teratogenic at physiological levels. In pregnancy, hyperkalemia or hypokalemia may cause adverse fetal effects; however, at therapeutic doses, no increased risk of congenital anomalies has been reported across trimesters. There is no evidence of teratogenicity in animal studies. |
■ FDA Black Box Warning
NO BLACK BOX WARNING
| Serious Effects |
["Hypersensitivity to potassium chloride or any component","Hyperkalemia (serum potassium >5.5 mEq/L)","Severe renal impairment with oliguria or anuria","Patients with untreated Addison's disease","Acute dehydration","Heat cramps","Hyperkalemic periodic paralysis"]
| Precautions | ["Hyperkalemia risk, especially in renal impairment","Monitor serum potassium levels frequently","Use with caution in patients with cardiac disease, conduction disorders, or medullary sponge kidney","Avoid in patients with metabolic alkalosis","Risk of volume overload in patients with heart failure or renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels, renal function, and acid-base balance. Continuous ECG monitoring recommended during intravenous administration due to risk of arrhythmias from hyperkalemia. In pregnancy, monitor fetal heart rate during infusion due to potential maternal electrolyte disturbances affecting fetal well-being. |
| Fertility Effects | No adverse effects on fertility have been reported with potassium chloride at therapeutic doses. Electrolyte imbalances (hyper- or hypokalemia) may secondarily affect reproductive function, but direct fertility impairment is not established. |